论文部分内容阅读
三九集团是由原国家经贸委、中国人民解放军总后勤部批准成立的直属国务院国资委管理的国有大型中央企业。集团主营核心是医药健康产业,是以生命健康为主业,多元化经营的大型国资企业集团。拥有总资产150亿元,品牌价值达83.06亿元,下属100多家企业。集团控股拥有三九医药、三九发展、三九生化三家上市公司和20多家通过 GMP 认证的医药生产企业,其多种药品被列入中国医保目录。
The Sanjiu Group is a state-owned large-scale state-owned enterprise directly managed by SASAC under the approval of the former State Economic and Trade Commission and the General Logistics Department of the Chinese People’s Liberation Army. The core of the Group is the medical and health industry, which is a large-scale state-owned enterprise group based on life and health and diversified operation. With total assets of 15 billion yuan, the brand value of 8.306 billion yuan, more than 100 affiliated enterprises. Group Holdings has 39 pharmaceutical, 39 development, three nine three biochemical three listed companies and more than 20 through the GMP certification of the pharmaceutical manufacturing enterprises, a variety of drugs are included in the China Medicare directory.